FDA-APPROVED INDICATIONS

OVERVIEW COPD
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction is generally progressive, may be accompanied by airway hyperreactivity, and may be partially reversible. 15 This progressive persistent obstruction or limitation of airflow is associated with an enhanced chronic inflammatory response in both the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients. COPD continues to be a leading cause of chronic morbidity and mortality worldwide carrying with it significant economic and social burden. 16 COPD is projected by the World Health Organization (WHO) to become the third leading cause by 2030. 17 In 2011, the CDC's National Health Interview Survey reported that an average of 26% of individuals in the U.S. over the age of 45 diagnosed with COPD reported breathing difficulty significant enough to limit activities. 18 This demonstrated a steady increase of 3 points since 2008 which may be suggestive of the potential increasing burden of COPD. However, the U.S. Preventive Services Task Force (USPSTF) recommends against routine screening in asymptomatic adults. 19 Although the precise distinctions between chronic bronchitis and emphysema are a subject of debate, common belief holds that chronic bronchitis is responsible for 85% of COPD. 20 Patients with chronic bronchitis experience intermittent airway inflammation and excessive mucus production that leads to frequent, prolonged episodes of productive cough. In contrast, 15% of patients with COPD suffer primarily from emphysema, in which destruction of the infrastructure of alveoli and distal airspaces that provide gas exchange and elastic recoil occurs. 21 Both chronic bronchitis and emphysema predispose patients to a common collection of symptoms and impairments in respiratory function, such as reductions in forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow (FEF25-75%).
The 2016 updated Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of COPD guidelines stresses a diagnosis of COPD should be considered in any individual who has dyspnea, chronic cough/sputum production, and a history of exposure to risk factors specific to the disease. Spirometry is required to effectively establish a clinical diagnosis of COPD. A postbronchodilator FEV1/FVC < 0.7 confirms presence of airflow limitation and a diagnosis of COPD. The assessment of FEV1 alone is a poor descriptor of disease status. Therefore, individual assessment of the patient's symptoms, future risks of exacerbations, severity of airflow limitation, and comorbidities is essential in guiding therapy. The GOLD Classification of Airflow Limitation, which is divided into 4 Grades (GOLD 1 [mild] to GOLD 4 [very severe]), utilizes these airflow limitation grades in addition to the number of exacerbations/hospitalizations. A COPD exacerbation is defined as an acute event characterized by worsening of the patient's respiratory symptoms that varies recommend the use of long-acting beta2-agonists (Grade 1B) and long-acting antimuscarinics (Grade 1A) over no treatment in patients with moderate to severe COPD, stating that long-acting antimuscarinics are preferred (Grade 1C). Likewise, they recommend short-acting antimuscarinic agents for monotherapy over short-acting beta2-agonists (Grade 2C) but further state that the combination is also preferred over short-acting beta2-agonist monotherapy (Grade 2B). However, long-acting beta2-agonist or anticholinergic monotherapy is preferred over short-acting antimuscarinic monotherapy (Grade 2C and Grade 1A, respectively). Long-acting combination therapy, including inhaled corticosteroids, is also preferred over monotherapy in patients with severe COPD (range, Grade 1B to 1C). Overall, recommendations in these guidelines are based on qualifying patients as those with mild, moderate, or severe COPD rather than GOLD classification or high-risk.
The 2016 GOLD guidelines recommend treatment plans for COPD based on the aforementioned patient group categories, identified by disease severity (airflow limitation), symptoms, comorbidities and exacerbation/hospitalization risk. 31 Bronchodilator medications continue to be central to symptom management in COPD across all groups. For patients with fewer symptoms and a low risk of exacerbations (Group A), a short-acting inhaled bronchodilator (beta2-agonist or anticholinergic) used on an as-needed basis is recommended as first choice while a long-acting beta2-agonist or anticholinergic and the combination of short-acting inhaled beta2-agonist and short-acting anticholinergic are considered as alternatives. For COPD patients who have more significant symptoms but low risk of exacerbations (Group B), regular use of a long-acting bronchodilator (beta2-agonist or anticholinergic) is recommended while the combination of a long-acting beta2-agonist and a longacting anticholinergic is an alternative treatment. There is insufficient evidence to recommend one long-acting agent over another. The choice between a beta2-agonist, anticholinergic, theophylline, or combination therapy depends on individual response in terms of symptom relief and adverse effects.
Initial treatment for Group C patients focuses on fixed combinations of inhaled corticosteroid/longacting bronchodilators (beta2-agonist or anticholinergic). 32 Alternatively, Group C patients may be initiated on a phosphodiesterase-4 (PDE4) inhibitor plus a long-acting bronchodilator (beta2-agonist or anticholinergic) or a long-acting anticholinergic plus a long-acting beta2-agonist. Group D patients with the most severe symptoms and risks of exacerbations may utilize the same initial therapeutic plan as those in Group C with a goal of reducing exacerbations. There is some evidence for use of triple therapy for Group D patients: inhaled corticosteroid plus 2 long-acting inhaled bronchodilators. 33 PDE4 inhibitors have been included in the guidelines as a substitute alternate agent in double or triple therapy. They tend to have stronger evidence for use if the patient has chronic bronchitis, severe COPD, or frequent exacerbations inadequately controlled by long-acting bronchodilators. Long-term monotherapy with inhaled corticosteroids at any stage has been shown to be less effective than its use in combination with long-acting beta2-agonists.
The 2011 ACP/ACCP/ATS/ERS guidelines do not support routine treatment with bronchodilators in the asymptomatic "At Risk" group as there are limited data to support that such treatment influences the trajectory of the disease. 34 Albeit a weak recommendation, the 2011 guidelines do suggest that stable, symptomatic COPD patients with an FEV1 between 60% and 80% may be treated with inhaled bronchodilators (anticholinergics or long-acting beta2-agonists). For stable, symptomatic patients with an FEV1 less than 60%, monotherapy with an inhaled bronchodilator is strongly recommended. The type of bronchodilator may be selected based on patient parameters, cost, and adverse effect profile. Combination therapy with an inhaled long-acting beta2-agonist, inhaled long-acting anticholinergic, or inhaled corticosteroid may be used in lieu of monotherapy for patients with FEV1 less than 60%; however, the group has offered this as a weak recommendation due to the moderate quality evidence. Further, the guidelines suggest there is no clear outline for which patients would benefit the most from combination therapy over monotherapy. However, the previous American Thoracic Society (ATS) and European Respiratory Society (ERS) 2004 Joint Standards for the Diagnosis and Management of COPD suggest that combining long-acting inhaled beta-agonists and ipratropium leads to fewer exacerbations than either drug alone. 35 Intermittent use of short-acting beta-agonists is not addressed. At present, no treatment is shown to modify the rate of decline in lung function. 36 Alternative treatment options include smoking cessation programs and products, corticosteroids, pulmonary rehabilitation, and the use of long-term oxygen therapy. Roflumilast (Daliresp), a PDE4 inhibitor indicated to decrease the frequency of exacerbations or worsening of symptoms of severe COPD, was not mentioned in these guidelines as they do not address severe COPD. 37 When comparing the efficacy of the inhaled medications, most of the trials reviewed did not demonstrate any differences between the agents. Trials did show that monotherapy with a long-acting inhaled agent (long-acting anticholinergic, long-acting beta2-agonist or corticosteroid) was superior to placebo or short-acting anticholinergic therapy in reducing exacerbation.
With the conversion to required chlorofluorocarbon (CFC)-free inhalers, the CFC-free combination albuterol-ipratropium MDI (Combivent Respimat) has been approved for use in the treatment of COPD.
Other agents within this class include an oral agent, roflumilast (Daliresp) 
Asthma
Medications to treat asthma are classified as controllers or relievers. Controllers are medications taken daily on a long-term basis to maintain asthma control. Relievers are medications used on an as-needed basis that act quickly to reverse bronchoconstriction and relieve symptoms. 38 The mainstay of asthma therapy is the use of ICS drugs and LABAs as controller medications. 39 These agents lead to improvements in lung function and symptoms and reduce the need for short-acting beta2-agonists (SABAs) for quick relief.
In 2007, the National Asthma Education and Prevention Panel (NAEPP) released a summary of the third report of the Expert Panel (EPR-3) and recommend that, for patients over age 5 years with moderate persistent asthma or asthma not controlled by low-dose corticosteroids, consideration be given for use of a combination of ICS and LABAs or for increasing the dose of ICS. 40 Long-acting anticholinergic agents, such as tiotropium (Spiriva Respimat), are not addressed for chronic management in these guidelines; however, the guidelines do include dosing of anticholinergic agents, such as ipratropium for the emergency management of acute asthma exacerbations in combination with albuterol or as an alternative to albuterol.
The 2016 GINA guidelines offer a control-based management plan to adjust treatment in a continuous cycle of assessment, treatment, and review of the patient's response as it relates to symptom control, future risk of exacerbations, and side effects. 41 Equally important in this process is identifying the patient's own goals regarding their asthma management to ensure improved outcomes. During this continuous cycle, a stepwise treatment approach is offered to achieve control using the patient's current level of control as the baseline. If the patient is not controlled on the current regimen, treatment should be stepped up until control is achieved. If control is maintained for at least 3 months on the current regimen, treatment can be stepped down to the lowest step and dosage that maintains control. Tiotropium is considered as an alternative add-on controller medication for patients in Step 4, which recommends ≥ 2 controller medications plus an as-needed reliever medication; it is not considered a preferred treatment.
Tiotropium inhalational spray (Spiriva Respimat) has been approved for the treatment of asthma in patients ≥ 12 years of age. Multiple other medications are indicated for the treatment of asthma and information can be found in other class reviews. Aclidinium, glycopyrrolate, tiotropium, and umeclidinium have similar affinity to the muscarinic receptor subtypes M1 to M5. 56, 57 However, in the airways, they exhibit pharmacological effects through inhibition of M3-receptors at the smooth muscle. This functional selectivity for M3 receptors is due to their ability to dissociate significantly faster from M2 receptors than from M3 receptors, unlike ipratropium. 58 Aclidinium association rate for the M3 receptor was similar to ipratropium and 2.6 times faster than tiotropium.
Roflumilast (Daliresp) and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4). This action leads to the accumulation of cyclic adenosine monophosphate (cAMP) in lung tissue. The specific mechanism by which roflumilast exerts its therapeutic action in patients with COPD still is not well-defined.
A combination albuterol and ipratropium (Combivent Respimat) enables simultaneous administration to produce greater bronchodilator effect than possible with either drug alone. Both ingredients exert a local effect on the muscarinic and beta2 receptors in the lung. In vitro clinical data showed that umeclidinium (Incruse Ellipta) was mostly absorbed from the lung after inhaled doses with minimum contribution from oral absorption. Umeclidinium is primarily metabolized by CYP2D6 and is a P-gp substrate; metabolites have either low or no pharmacological activity. Following oral dosing to healthy male subjects, 92% of the total dose was recovered in feces, and in urine recovery was less than 1% of the total dose. The effective half-life after once-daily inhalation dosing is 11 hours.
Following inhalation of umeclidinium/vilanterol (Anoro Ellipta), maximum concentration is reached in 5 to 15 minutes and is mostly absorbed from the lung with minimum contribution from oral absorption.
In vitro data indicates umeclidinium is primarily metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). The primary metabolic routes for umeclidinium are oxidative (hydroxylation, O-dealkylation) followed by conjugation (e.g., glucuronidation). The metabolites formed have low or no pharmacological activity. Approximately 92% of the drug is excreted via feces with 1% via urine. Metabolism of vilanterol primarily occurs via hepatic CYP3A4 with the metabolites having significantly reduced beta1-and beta2-agonist activity. Both umeclidinium and vilanterol are a substrate for the Pglycoprotein (P-gp) transporter. Following oral administration, vilanterol metabolites are excreted mainly via urine (70%) and feces (30%).
Data on the tiotropium component of tiotropium/olodaterol (Stiolto Respimat) are comparable to those for tiotropium solutions described above. Olodaterol reaches maximum plasma concentrations within 10 to 20 minutes following inhalation, and inhaled bioavailability is 30% (oral bioavailability is negligible All LABAs (Anoro Ellipta, Bevespi Aerosphere, Stiolto Respimat, Utibron Neohaler) are contraindicated and carry a boxed warning in patients with asthma without use of a long-term asthma control medication due to the risk of asthma related death.
Roflumilast is contraindicated for use in patients with moderate to severe liver impairment (Child-Pugh B or C). Psychiatric adverse events (insomnia, depression, and anxiety) were twice as frequent in patients taking roflumilast in controlled trials as compared to placebo. One completed suicide and 2 suicide attempts were reported in clinical trials; post-marketing has produced reports of suicidal ideation in patients with and without a history of depression. All patients should be monitored for signs of suicidal ideation. For patients with a history of depression and/or suicidal thoughts or behavior, prescribers should carefully weigh the risks and benefits before use. Moderate (5% to 10% of body weight) and severe (> 10% of body weight) weight loss have been reported with roflumilast therapy. Weight was regained after discontinuation of therapy.
Inhaled medicines may cause paradoxical bronchospasm, which may be life-threatening. If this occurs, treatment with any of these products should be stopped and other alternatives considered.
Aclidinium, glycopyrrolate, ipratropium, tiotropium, and umeclidinium should be used with caution in patients with narrow-angle glaucoma or urinary retention. Patients should consult with a physician immediately if symptoms of prostatic hyperplasia or bladder-neck obstruction occur.
Clinically significant cardiac effects, including electrocardiogram (ECG) effects, may occur with excessive LABA use; do not use at doses higher than recommended. Dose may need to be decreased if these effects occur when using the recommended dose. Similarly, beta-agonists may cause hypokalemia, potentially adding to cardiac concerns. Cardiovascular effects and fatalities have been reported in association with overuse of inhaled sympathomimetic medications. When using these medications other LABAs should not be used.
Sympathomimetic agents, including albuterol and LABAs, should be used cautiously in patients with convulsive disorders, thyrotoxicosis, suspected QT prolongation, and those with known sympathomimetic sensitivity. These agents may also cause hyperglycemia.
Risk Evaluation and Mitigation Strategies (REMS) 87
None of the products under review require a medication guide or a REMS program. Monoamine oxidase (MAO) inhibitors and tricyclic antidepressants should be used cautiously with albuterol-containing products, such as albuterol/ipratropium inhalation solution, and albuterol/ipratropium CFC-free MDI due to the potentiation of cardiovascular effects. A 2-week discontinuation period of the MAO inhibitors and tricyclic antidepressants is suggested prior to initiating therapy with an albuterol-containing product.
DRUG INTERACTIONS
Due to their sympathomimetic effects, LABAs should be used cautiously with adrenergic drugs, other sympathomimetics, xanthine derivatives, steroids, MAO inhibitors, tricyclic antidepressants, betablockers, and agents that prolong the QT interval. If co-administration is necessary due to lack of an acceptable alternative therapy, a cardioselective beta-blocker could be utilized to limit severe bronchospasm.
Due to the potential for hypokalemia with LABAs, they should be used cautiously with diuretics.
Anticholinergic agents within this class should be avoided with other anticholinergic medications.
Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, cimetidine) will increase roflumilast (Daliresp) systemic exposure and may result in increased adverse reactions. The risk of such concurrent use should be weighed carefully against benefit.
Caution is advised when considering the co-administration of umeclidinium/vilanterol with ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, voriconazole) due to increased risk of adverse effects, including cardiovascular (e.g., QT prolongation). The most common adverse event reported with tiotropium was dry mouth (16%). Additionally, use of tiotropium inhalation spray (Spiriva Respimat) has been associated with pharyngitis, cough, and sinusitis. Other reports of adverse events with tiotropium are consistent with anticholinergic effects, including constipation (4%) and blurred vision.
In 1 trial that enrolled 198 COPD patients, the number of patients with changes from baselinecorrected QT interval of 30 to 60 msec was higher in the tiotropium-treated group (range, 16% to 20%) as compared to the placebo group (range, 1% to 12%) depending on QT correction method used. Other clinical studies did not detect a drug effect on QTc intervals.
In 2008, the FDA issued a MedWatch related to of the potential for tiotropium to increase the risk of stroke in patients. 116 However, in 2010, the FDA completed its review and issued a statement that the available data did not support the association between tiotropium use and an increase risk for stroke, myocardial infarction, or death from a cardiovascular event.
Common adverse reactions associated with aclidinium, when compared to placebo, include nasopharyngitis (5.5%), cough (3%), and dry mouth (< 1%).
Common adverse events (incidence ≥ 2% and more common than placebo) associated with the use of umeclidinium (Incruse Ellipta) include nasopharyngitis, upper respiratory tract infection, cough, and arthralgia.
The most common adverse reactions occurring in more than 1% of umeclidinium/vilanterol (Anoro Ellipta) patients were pharyngitis (2%), diarrhea (2%), and extremity pain (2%). Sinusitis, constipation, lower respiratory tract infection, muscle spasms, and neck pain have also been reported.
The most common adverse reactions reported in ≥ 3% of patients using tiotropium/olodaterol (Stiolto Respimat) in clinical trials were nasopharyngitis, cough, and back pain.
The most common adverse effects with an incidence ≥ 1% for glycopyrrolate (Seebri Neohaler) include upper respiratory tract infections, urinary tract infections, oropharyngeal pain, nasopharyngitis, and sinusitis.
Additional adverse effects reported with glycopyrrolate/indacaterol (Utibron Neohaler) include hypertension and back pain.
The 2 most common adverse events reported with roflumilast (Daliresp) were diarrhea (9.5%) and weight loss (7.5%). 
SPECIAL POPULATIONS
Geriatrics
Dose adjustments are not required in geriatric patients.
Pregnancy
Albuterol, albuterol/ipratropium CFC-free MDI, albuterol/ipratropium inhalation solution, roflumilast, aclidinium, formoterol/glycopyrrolate, glycopyrrolate, glycopyrrolate/indacaterol, tiotropium, tiotropium/olodaterol, umeclidinium, and umeclidinium/vilanterol are Pregnancy Category C. Ipratropium is Pregnancy Category B.
Renal and/or Hepatic Impairment
The pharmacokinetics of ipratropium have not been studied in patients with renal or hepatic insufficiency.
Since tiotropium is predominantly renally excreted, renal impairment was associated with increased plasma drug concentrations and reduced drug clearance. Patients with moderate to severe renal impairment (creatinine clearance of ≤ 50 mL/min or < 60 mL/min for tiotropium solution) should be monitored closely for anticholinergic side effects when treated with tiotropium or tiotropiumcontaining products (Stiolto Respimat).
No dose adjustment of tiotropium/olodaterol is required in patients with mild to moderate hepatic impairment, but this agent has not been studied in severe hepatic impairment.
No dosage adjustment of roflumilast is necessary in patients with renal impairment. Roflumilast is not recommended for use in patients with moderate to severe liver impairment (Child-Pugh B or C).
No dosage adjustment of aclidinium (Tudorza Pressair) is needed for patients with renal or hepatic impairment.
Umeclidinium (Incruse Ellipta) showed no relevant increases in exposure in patients with moderate hepatic impairment (Child-Pugh score of 7 to 9) and no dose adjustment is required in patients with renal impairment. No dosage adjustment of umeclidinium/vilanterol (Anoro Ellipta) is required for patients with renal impairment or patients with moderate hepatic impairment.
No dose adjustment of glycopyrrolate or indacaterol/glycopyrrolate is required in patients with mild to moderate renal or hepatic impairment. Neither agent has been studied in severe hepatic impairment, and use in severe renal impairment should only be when the benefits clearly outweigh the risks of increased exposure.
No formal studies of formoterol/glycopyrrolate have been conducted in patients with hepatic or renal failure. However, formoterol is primarily cleared by hepatic metabolism and impairment might lead to accumulation of formoterol. Monitoring is recommended. In patients with severe renal impairment (creatinine clearance ≤ 30 mL/min/1.73 m 2 ) or end-stage renal disease requiring dialysis, the medication should be used only when benefits outweigh the risk. 
CLINICAL TRIALS Search Strategy
Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Randomized, controlled, comparative trials are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance.
COPD aclidinium DPI (Tudorza Pressair) versus placebo
Three randomized, double-blind, placebo-controlled trials, compared aclidinium dry powder for inhalation 400 mcg or 200 mcg twice daily and placebo in patients (n=1,919) with stable, moderate to severe COPD. Two trials were 12 weeks in duration and one was 24 weeks. The primary efficacy endpoint was change from baseline in morning trough FEV1 at study's end. Other efficacy variables included peak FEV1 and St. George's Respiratory Questionnaire (SGRQ), rescue medication usage, and COPD exacerbations. The SGRQ measures the impact on overall health, daily life, and perceived wellbeing in patients with obstructive airways disease. 146 It is also designed with a responder rate threshold of an improved score of 4 or more. The effect size for aclidinium 400 mcg ranged from 72 mL to 124 mL across the 3 trials at Week 12, and the treatment effect persisted at Week 24 (p<0.001 for all trials). 147, 148 Aclidinium 200 mcg also demonstrated a statistically significant difference in spirometry from placebo, although the magnitude of the treatment difference (51 to 86 mL) was smaller than the effect size observed for the 400 mcg dose. In addition, lack of efficacy was cited more frequently as a reason for discontinuation in the placebo and aclidinium 200 mcg arms compared to aclidinium 400 mcg. Greater decreases in total SGRQ scores were observed for aclidinium compared to placebo (p<0.001). Six-and 12-month extension studies suggested a decrease in rate of exacerbations with aclidinium. Results from the 6-month study were less consistent, although this variability may be due in part to a low background rate of exacerbations overall. Use of daily rescue medication changed by as much as -1.2 puffs/day in the aclidinium 400 mcg arm, compared to -0.3 puffs/day in the placebo group. The 200 mcg dosage was not FDA approved.
In a phase 3 efficacy and safety trial (ACCORD I), 561 patients were randomized (1:1:1) to twice daily aclidinium 200 mcg, 400 mcg, or placebo. 149 Primary endpoint was change from baseline in trough FEV1; secondary endpoint was peak FEV1. A large, randomized, double-blind, double-dummy, 2-period crossover study of 172 patients with COPD investigated the effects of the addition of either formoterol or albuterol to ipratropium in patients whose symptoms were not optimally controlled by ipratropium alone. 150 In addition to ipratropium MDI 40 mcg 4 times daily, patients received, in random order, formoterol DPI 12 mcg twice daily for 3 weeks followed by albuterol MDI 200 mcg 4 times daily for 3 weeks, or vice versa. Morning peak expiratory flow rate (PEFR) and FEV1 were significantly better with the formoterol-ipratropium combination than with the albuterol-ipratropium combination (p=0.0003 and p<0.0001 for PEFR and FEV1, respectively). Similar findings were noted for FVC. On average, all mean individual symptom scores were lower for patients receiving the formoterol-ipratropium combination than for those receiving the albuterol-ipratropium combination (p=0.0042). There were no significant differences between the formoterol and albuterol groups in mean percentage of days with no rescue drug (72.3% and 68.8%, respectively), the number of patients with no COPD exacerbations (34.6% and 30.8%, respectively), or the percentage of patients experiencing "bad days" during the trial (65% and 69%, respectively).
formoterol/glycopyrrolate (Bevespi Aerosphere) versus placebo
The safety and efficacy of glycopyrrolate/formoterol (Bevespi Aerosphere) were assessed in 2 placebocontrolled lung function trials of 24 weeks. 151 Trial 1 and Trial 2, 24 week, randomized, double-blind, placebo-controlled, parallel-group confirmatory trials, were conducted in patients with moderate to very severe COPD (n=3,699; ages 40 to 80 years old; history of smoking ≥ 10 pack-years; post-albuterol FEV1 < 80% of predicted normal values; FEV1/FVC ratio < 0.7). 152 Trial 1 and Trial 2 evaluated glycopyrrolate/formoterol 18 mcg/9.6 mcg, glycopyrrolate 18 mcg, formoterol 9.6 mcg, and placebo twice daily. Trial 1 also had an open-label active control. In both trials glycopyrrolate/formoterol showed a larger increase in mean change from baseline in trough FEV1 at week 24 compared to placebo (150 mL and 103 mL, respectively), glycopyrrolate (59 mL and 54 mL, respectively), and formoterol (64 mL and 56 mL, respectively), the primary endpoint. In Trial 1 and Trial 2, the mean peak FEV1 improvement from baseline compared to placebo at week 24 was 291 mL (95% CI, 252 to 331) and 267 mL (95% CI, 226 to 308), respectively. Glycopyrrolate/formoterol also showed an onset of bronchodilatory effect at 5 minutes after the first dose based on a mean increase in FEV1 compared to placebo in both trials. In Trial 1, the SGRQ responder rate (defined as an improvement in score of ≥ 4) was 37%, 30%, 35%, and 28% for glycopyrrolate/formoterol, glycopyrrolate, formoterol, and placebo, respectively, with odds ratios of 1.4 (95% CI, 1.1 to 1.8), 1.1 (95% CI, 0.9 to 1.5), and 1.5 (95% CI, 1.1 to 2.1) for glycopyrrolate/formoterol versus glycopyrrolate, glycopyrrolate/formoterol versus formoterol, and glycopyrrolate/formoterol versus placebo, respectively. Trends were similar in Trial 2 with odds ratios of 1.2 (95% CI, 0.9 to 1.6), 1.3 (95% CI, 1.9 to 1.7), and 1.3 (95% CI, 0.9 to 1. 
indacaterol/glycopyrrolate (Utibron Neohaler) versus placebo
The safety and efficacy of indacaterol/glycopyrrolate were evaluated in 2 placebo-controlled confirmatory trials, and a 12-month long-term safety trial in COPD patients (n=615). The efficacy is based on the dose ranging trials which included 562 COPD or asthma patients and the confirmatory trials of 2,038 patients. 154 In the confirmatory trials, the active-controls in these trials were the individual components of the product, indacaterol 27.5 mcg twice daily and glycopyrrolate twice daily, and were included to approximate the contribution each product makes in improved FEV1. The primary endpoint of the 12-week, randomized, double-blind, placebo-and active-controlled, parallel group confirmatory trials was the least squares mean change from baseline in FEV1 AUC(0-12h) following the morning dose of indacaterol/glycopyrrolate (27.5/15.6 mcg) at day 85 compared to placebo. 
roflumilast (Daliresp) versus placebo
Multiple clinical trials comparing roflumilast to placebo have demonstrated its efficacy in COPD patients. 155 A phase 3, multicenter, double-blind, randomized, placebo-controlled study assigned 1,411 patients with COPD to roflumilast 250 mcg (n=576), roflumilast 500 mcg (n=555), or placebo (n=280) given once daily for 24 weeks. 156 Primary outcomes were post-bronchodilator FEV1 and health-related quality of life. Secondary outcomes included other lung function parameters and COPD exacerbations. Postbronchodilator FEV1 at the end of treatment significantly improved with roflumilast 250 mcg (+74 mL) and roflumilast 500 mcg (+97 mL) compared with placebo (p<0.0001). Improvement in health-related quality of life was greater with roflumilast 250 mcg (-3.4 units) and roflumilast 500 mcg (-3.5 units) than with placebo (-1.8 units), but the differences were not significant. The mean numbers of exacerbations per patient were 1.13, 1.03, and 0.75 with placebo, roflumilast 250 mcg, and roflumilast 500 mcg, respectively. Most adverse events were mild to moderate in intensity.
Two double-blind, multicenter trials studied patients older than 40 years with moderate-to-severe COPD who were randomly assigned to roflumilast 500 mcg or placebo once daily for 24 weeks in addition to salmeterol or tiotropium. 157 The primary endpoint was change in pre-bronchodilator FEV1.
In the salmeterol/roflumilast trial, 466 patients were assigned to and treated with roflumilast and 467 with placebo; in the tiotropium/roflumilast trial, 371 patients were assigned to and treated with roflumilast and 372 with placebo. Compared with placebo, roflumilast consistently improved mean pre-bronchodilator FEV1 by 49 mL (p<0.0001) in patients treated with salmeterol, and 80 mL (p<0.0001) in those treated with tiotropium. Similar improvement in post-bronchodilator FEV1 was noted in both groups. Roflumilast had beneficial effects on other lung function measurements in both groups. Nausea, diarrhea, weight loss, and headache were more frequent in roflumilast patients. This study was funded by the manufacturer.
In 2 placebo-controlled, double-blind, multicenter trials, patients with COPD older than 40 years with severe airflow limitation, bronchitis symptoms, and a history of exacerbations were randomly assigned to roflumilast 500 mcg daily or placebo for 52 weeks. 158 Primary endpoints were change in prebronchodilator FEV1 and the rate of exacerbations that were moderate (glucocorticosteroid-treated) or severe. Patients were assigned to treatment, stratified according to smoking status and treatment with long-acting beta agonists, and given roflumilast (n=1,537) or placebo (n=1,554). In both studies, the primary endpoints were achieved and were similar in magnitude. In a pooled analysis, prebronchodilator FEV1 increased by 48 mL with roflumilast compared with placebo (p<0.0001). The rate of exacerbations that were moderate or severe per patient per year was 1.14 with roflumilast and 1.37 with placebo (reduction 17%; p<0.0003). Adverse events were more common with roflumilast. In the pooled analysis, the difference in weight change during the study between the roflumilast and placebo groups was -2.17 kg. This study was funded by the manufacturer. No trials have been conducted to assess the effects of roflumilast on COPD exacerbations when added to a fixed-dose combination product containing a long-acting beta agonist and inhaled corticosteroid. 159
tiotropium (Spiriva) versus placebo
The Understanding the Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial was a large, randomized, double-blind, placebo-controlled trial that compared 4 years of therapy with either tiotropium or placebo in 5,993 patients with COPD who were permitted to use all respiratory medications except inhaled anticholinergic drugs. 160 The patients were at least 40 years of age with an FEV1 of 70% or less after bronchodilation and a ratio of FEV1/FVC of 70% or less. The objective of the study was to determine whether treatment with tiotropium 18 mcg reduced the rate of decline of FEV1 over time in patients with COPD. The 2 co-primary endpoints were the yearly rate of decline in the mean FEV1 before the use of a study drug and short-acting bronchodilators in the morning (prebronchodilator) and after the use of a study drug (post-bronchodilator) from day 30 (steady state) until completion of double-blind treatment. Secondary endpoints included measures of rates of mean decline for both FVC and slow vital capacity (SVC), health-related quality of life as measured by the total score on SGRQ, exacerbations of COPD, and mortality. Patients were randomly assigned to the tiotropium group (n=2,987) or to the placebo group (n=3,006). Mean absolute improvements in FEV1 in the tiotropium group were maintained throughout the trial (ranging from 87 to 103 mL before bronchodilation and from 47 to 65 mL after bronchodilation), as compared with the placebo group (p<0.001). After day 30, the differences between the 2 groups in the rate of decline in the mean FEV1 at any time point were not significant. The mean absolute total score on the SGRQ was lower, indicating improvement, in the tiotropium group compared with the placebo group at each time point throughout the 4-year period (p<0.001). At 4 years and 30 days, tiotropium treatment was associated with a reduction in the risks of exacerbations, related hospitalizations, and respiratory failure, but tiotropium did not significantly reduce the rate of decline in FEV1.
In a subgroup analysis of the UPLIFT trial, data from 2,739 participants diagnosed with COPD (GOLD stage 2) were examined. 161 The tiotropium group had a statistically insignificant lower decline of prebronchodilator FEV1 than the control group (35 mL per year versus 37 mL per year, p=0.38) and lower post-bronchodilator FEV1 (43 mL per year versus 49 mL per year, p=0.024). SGRQ scores were lower in the tiotropium group than the control group (p≤0.006 for all time points), indicating a statistically significant improved health status. Mean number of exacerbations was lower in the tiotropium group than the control group (0.56 per patient-year versus 0.70 per patient-year, p<0.0001). The results of this subgroup analysis provided further support for the rationale of starting a long-acting anticholinergic in patients with moderate COPD.
tiotropium (Spiriva) versus ipratropium (Atrovent)
The Dutch Tiotropium Group evaluated and compared the efficacy and safety of tiotropium and ipratropium during long-term treatment of patients with stable COPD. 162 Two-hundred eighty-eight patients with mean age 65 years and mean FEV1 41% of predicted value participated in a 14-center, double-blind, double-dummy, parallel group study. Patients were randomized to receive either tiotropium 18 mcg once daily from a dry powder inhaler (HandiHaler; two thirds of patients) or ipratropium 40 mcg 4 times daily from a metered dose inhaler (one third of patients) for 13 weeks. Outcome measures were lung function, daily records of PEF, and the use of concomitant albuterol. During treatment, tiotropium achieved a significantly greater improvement than ipratropium in trough, average, and peak FEV1 levels, trough and average FVC levels, and weekly mean morning and evening PEF. The use of concomitant albuterol was also significantly lower in the tiotropium group (p<0.05). The only drug related adverse event was dry mouth (tiotropium 14.7% versus ipratropium 10.3%).
Two, 1-year, randomized, double-blind, double-dummy studies evaluated tiotropium 18 mcg once daily (n=356) with ipratropium 40 mcg 4 times daily (n=179). 163 Mean baseline FEV1 values were 41.9% of predicted value for tiotropium and 39.4% of predicted value for ipratropium. Trough FEV1 at 1 year improved by 0.12 +/-0.01 L with tiotropium and declined by 0.03 +/-0.02 L with ipratropium (p<0.001). Tiotropium reduced the number of exacerbations by 24% (p<0.01), increased time to first exacerbation (p<0.01), and the time to first hospitalization for a COPD exacerbation (p<0.05) compared with ipratropium. Apart from an increased incidence of dry mouth in the tiotropium group, adverse events were similar between treatments.
tiotropium (Spiriva) versus salmeterol (Serevent)
A 6-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group study in 623 patients (tiotropium, n=209; salmeterol, n=213; and placebo, n=201) evaluated tiotropium 18 mcg once daily via dry-powder inhaler compared with salmeterol 50 mcg twice daily via metered dose inhaler. The study was conducted in patients with a baseline mean FEV1 40% of predicted value and a mean age of 65 years. 164 Compared with placebo treatment, the mean predose morning FEV1 following 6 months of therapy increased significantly more for the tiotropium group (0.14 L) than the salmeterol group (0.09 L) (p<0.01). The difference between tiotropium and salmeterol was statistically significant (0.05 L; p<0.01). At study end, trough FVC had improved significantly above placebo at 0.25 L for tiotropium (p<0.001) and 0.13 L for salmeterol (p<0.001). The difference between tiotropium and salmeterol was 0.11 L (p<0.01). Both active drugs significantly reduced the need for rescue albuterol. Tiotropium patients also achieved meaningful changes in health-related quality of life compared to salmeterol patients.
Patients with COPD (tiotropium, n=402; salmeterol, n=405; placebo, n=400) were enrolled in two, 6-month, randomized, placebo controlled, double-blind, double-dummy studies of tiotropium 18 mcg once daily via HandiHaler or salmeterol 50 mcg twice daily via a metered dose inhaler. 165 The 2 trials were combined for analysis of health outcomes consisting of exacerbations, health resource use, dyspnea (assessed by the transitional dyspnea index, TDI), health-related quality of life (assessed by SGRQ), and spirometry. Compared with placebo, tiotropium, but not salmeterol, was associated with a significant delay in the time to onset of the first exacerbation. Fewer COPD exacerbations per patient year occurred in the tiotropium group (1.07 events/year), than in the salmeterol group (1.23 events/year; p=0.222) or in the placebo group (1.49 events/year; p<0.05). The tiotropium group had 0.1 hospital admissions per patient year for COPD exacerbations compared with 0.17 for salmeterol and 0.15 for placebo (p=NS). SGRQ total scores improved by 4.2, 2.8, and 1.5 units during the 6-month trial for the tiotropium, salmeterol, and placebo groups, respectively (p<0.01 tiotropium versus placebo). Compared with placebo, TDI focal score improved in both the tiotropium group (1.1 units, p<0.001) and the salmeterol group (0.7 units, p<0.05). The difference between tiotropium and salmeterol was not significant (p=0.17).
tiotropium (Spiriva) + placebo versus tiotropium (Spiriva) + salmeterol (Serevent) OR fluticasone/salmeterol (Advair®)
A randomized, double-blind, placebo-controlled trial was conducted in Canada with 449 patients with moderate to severe COPD who had 1 year of treatment with tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus fluticasone/salmeterol. 166 The proportion of patients in the tiotropium plus placebo group who had episodes of an exacerbation (62.8%) was not different from that in the tiotropium plus salmeterol group (64.8%; 95% CI, -12.8 to 8.8) or in the tiotropium plus fluticasone/salmeterol group (60%; 95% CI, -8.2 to 13.8). Tiotropium plus fluticasone/salmeterol improved lung function as measured by FEV1 (p=0.049) and disease-specific quality of life (p=0.01), reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53; 95% CI, 0.33 to 0.86), as well as all-cause hospitalizations (incidence rate ratio, 0.67; 95% CI, 0.45 to 0.99), compared with tiotropium plus placebo. In contrast, tiotropium plus salmeterol did not statistically improve lung function or hospitalization rates compared with tiotropium plus placebo. It is noteworthy that more than 40% of patients who received tiotropium plus placebo and tiotropium plus salmeterol discontinued therapy prematurely, and many crossed over to treatment with open-label inhaled corticosteroids or long-acting beta-agonists. The authors concluded that the addition of fluticasone/salmeterol to tiotropium therapy did not statistically influence rates of COPD exacerbation but did improve lung function, quality of life, and hospitalization rates in patients with moderate to severe COPD.
tiotropium (Spiriva) versus tiotropium (Spiriva) + formoterol (Foradil)
In a 12-week active-controlled, double-blind, multicenter trial, a total of 255 subjects with COPD were randomized to either a combination of formoterol 12 mcg twice daily plus tiotropium 18 mcg once daily in the morning or monotherapy with tiotropium 18 mcg once daily in the morning. 167 The primary efficacy variable was the area under the curve for FEV1measured 0 to 4 hours after the morning dosing (FEV1 AUC(0-4h)). Significantly greater improvements in the FEV1 AUC(0-4h) were seen with formoterol plus tiotropium versus tiotropium alone at all time points. At endpoint, FEV1 AUC(0-4h) increased 340 mL with formoterol plus tiotropium versus 170 mL with tiotropium alone (p<0.001). Improvements in trough FEV1 with formoterol plus tiotropium versus tiotropium alone were 180 mL and 100 mL, respectively (p<0.01). Significantly greater reductions from baseline in symptom scores (p<0.05) and daytime albuterol use (p<0.04) were seen at endpoint with combination formoterol plus tiotropium versus tiotropium monotherapy. Both treatments were well tolerated.
tiotropium inhalation spray (Spiriva Respimat) versus placebo
Five confirmatory trials of tiotropium inhalation spray were conducted that involved a total of 6,614 patients (Spiriva Respimat, n=2,801; placebo, n=2,798). Trials 1 and 2 were 12-week, randomized, double-blind, placebo-and active-(ipratropium) controlled trials that evaluated bronchodilation. 168 Trials 3 through 5 were 48-week, randomized, double-blind, placebo-controlled, trials that evaluated bronchodilation and effects on COPD exacerbations. The 5 trials enrolled patients who were 40 years of age or older with a clinical diagnosis of COPD, a history of smoking greater than 10 pack-years, an FEV1 less than or equal to 60% of predicted, and a ratio of FEV1/FVC of less than or equal to 0.7. All treatments were administered once-daily in the morning. Trials 1 through 4 utilized tiotropium inhalation spray 5 mcg and 10 mcg doses. Trial 5 only included the 5 mcg dose. The change from baseline in trough FEV1 was the primary endpoint in all trials. Trials 3 through 5 included COPD exacerbations as primary endpoints.
Tiotropium inhalation spray exhibited significant improvement in trough FEV1 compared to placebo in all 5 trials. The difference from placebo in trough FEV1 at the end of treatment (95% CI) was as follows: Trial 1 was 0.11 L, Trial 2 was 0.13 L, Trial 3 was 0.14 L, Trial 4 was 0.11 L, and Trial 5 was 0.1 L. For Trials 3 and 4, the pooled analysis of exacerbation rate per patient year was specified as a primary endpoint, while the primary endpoint for Trial 5 was time to first exacerbation, but included exacerbation rate per patient year as secondary endpoint. Exacerbations were defined as respiratory events/symptoms with a duration of ≥ 3 days with ≥ 2 of the following symptoms or new onset: shortness of breath/dyspnea/shallow rapid breathing, sputum production (volume), occurrence of purulent sputum, cough, wheezing, and chest tightness. In the analysis, Trials 3 and 4, tiotropium inhalation spray 5 mcg significantly reduced the number of COPD exacerbations compared to placebo with 0.78 exacerbations per patient year versus 1 exacerbation per patient year, respectively (RR, 0.78; 95% CI 0.67, 0.92). In Trial 5, treatment with tiotropium inhalation spray) delayed the time the time to first COPD compared to placebo (HR, 0.69; 95% CI, 0.63, 0.77); additionally, the exacerbation rate was also lower in tiotropium inhalation spray compared to placebo. In Trials 3 and 4, patients treated with tiotropium inhalation spray also used less rescue medication compared to patients on placebo.
In a sixth trial, a long-term, randomized, double-blind, double dummy, active-controlled trial that observed patients up to 3 years evaluated the risk of all-cause mortality associated with tiotropium inhalation spray (Spiriva Respimat, n=5,711) compared to tiotropium inhalation powder (Spiriva, n=5,694). The mean age was 65 years and approximately 70% of the subjects were male with the majority of the patients with GOLD 2 or GOLD 3 status (48% and 40% respectively). The mean postbronchodilator was FEV1 1.34 L with a mean FEV1/FVC ratio of 50%. Both treatment groups had a median exposure to treatment for 835 days. The all-cause mortality was found to be similar between both groups (HR, 0.96; 95% CI, 0.84 to 1.09).
tiotropium/olodaterol (Stiolto Respimat) versus tiotropium or olodaterol
The efficacy of Stiolto Respimat is based on two 4-week dose-ranging trials (n=592) and 2 multicenter, phase 3, replicate, randomized, 52-week, double-blind active-controlled trials (n=5,162; Study 1, n=2,624; Study 2, n=2,538) in patients with COPD. 169,170 Dose selection in the confirmatory trials was based on trials for the individual components of the drug, tiotropium and olodaterol. Patients were assigned to tiotropium/olodaterol (fixed combination) 2.5/5 mcg or 5/5 mcg, tiotropium 2.5 or 5 mcg, or olodaterol 5 mcg once daily via the Respimat inhaler for 52 weeks. Most patients were considered GOLD stage 2/3 (88.6%) and approximately one-third of patients were current smokers. The primary endpoint, FEV1 AUC(0-3h) at 24 weeks, was 241, 256, 139, and 133 mL in the tiotropium/olodaterol 2.5/5 mcg, tiotropium/olodaterol 5/5 mcg, tiotropium 2.5 mcg, tiotropium 5 mcg, and olodaterol 5 mcg groups, respectively (p<0.0001 for tiotropium/olodaterol 5/5 mcg compared single components). Significant differences between the 5/5 mcg fixed combination and the individual components were also seen in the SGRQ score at 24 weeks (p<0.05 for both comparisons). Adverse effects were comparable between groups. These trials were funded by the manufacturer of Stiolto Respimat.
umeclidinium (Incruse Ellipta) versus placebo
Two randomized double-blind, placebo-controlled, parallel-group studies (Study 1 = 24 weeks; Study 2 =12 weeks) were performed in patients with COPD to establish the efficacy of umeclidinium bromide on lung function. 171 Each study enrolled patients with COPD, 40 years of age and older, with a smoking history of 10 pack-years or more, had a post-albuterol FEV1 ≤ 70% of predicted normal values, with a Modified Medical Research Council (mMRC) score of ≥ 2, and with a ratio of FEV1/FVC of < 0.7. At the Study 1 screening, the mean post-bronchodilator percent predicted FEV1 was 47%, patients had a mean post-bronchodilator FEV1/FVC ratio of 0.47, and the mean percent reversibility was 15%. During Study 1, patients' received either umeclidinium bromide (62.5 mcg) or placebo. The primary endpoint was change from baseline in trough (predose) FEV1 at day 169 compared to placebo. The study concluded that umeclidinium bromide resulted in a larger increase in mean change from baseline in trough (predose) FEV1 compared to placebo (95% CI). Results from Study 2 were similar. SGRQ was used to measure patient health-related quality of life. Umeclidinium bromide showed an improvement in mean SGRQ total score compared with placebo at day 168 (-4.69; 95% CI, -7.07 to -2.31).
umeclidinium (Incruse Ellipta) versus placebo with background fluticasone furoate/vilanterol (Breo Ellipta) therapy
Two replicate, 12-week, double-blind, placebo-controlled, parallel-group multicenter trials assessed the efficacy of umeclidinium in 1,238 patients with COPD. 172 Patients were randomized 1:1:1 to umeclidinium 62. . The 0 to 6 hour weighted mean FEV1 values on day 84 compared to placebo were also significant. Results with the SGRQ were inconsistent; a difference was found in both studies with the 62.5 mcg dose but differed between studies using the 125 mcg dose. Adverse effects among groups were similar.
umeclidinium/vilanterol (Anoro Ellipta) versus umeclidinium versus vilanterol versus placebo
Two 6-month randomized, double-blinded, placebo-controlled, parallel-group clinical trials were performed to evaluate the efficacy of umeclidinium/vilanterol on lung function in patients with COPD. 173, 174 In Trial 1, a total of 1,532 patients were randomized (3:3:3:2) to umeclidinium/vilanterol 62.5 mcg/25 mcg, umeclidinium 62.5 mcg, vilanterol 25 mcg, and placebo once daily using a dry powder inhaler (DPI). Primary endpoint was change from baseline in trough FEV1 at day 169 (defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous dose on day 168) compared with placebo and the individual components. All active treatments produced statistically significant improvement in trough FEV1 compared with placebo on day 169 (0.072 to 0.167 L; all p<0.001). FEV1 increases were significantly greater than the individual components (0.052 to 0.095 L; p≤0.004). 
umeclidinium/vilanterol (Anoro Ellipta) versus tiotropium (Spiriva HandiHaler)
A 24-week, multicenter, multinational, double-blind, double-dummy, parallel-group, randomized controlled trial compared the efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg once daily and tiotropium 18 mcg once daily in patients ≥ 40 years with moderate to severe COPD (n=905). 176 Patients with pneumonia or hospitalization within the past 12 weeks were excluded. Rescue medication (albuterol) and consistently dosed inhaled corticosteroids were allowed. At Day 169, umeclidinium/vilanterol was superior to tiotropium in the primary outcome, trough Two 12-week, multicenter, double-blind, parallel-group, double-dummy, randomized trials compared the efficacy of umeclidinium/vilanterol to fluticasone/salmeterol in patients with moderate to severe COPD (Study 1, n=706; Study 2, n=697). 177 Patients with infrequent exacerbations were randomized 1:1 to once-daily umeclidinium/vilanterol 62. Efficacy of tiotropium bromide inhalation spray is based on 5 confirmatory trials in non-smoking adults (n=3,476) and 2 trials in adolescents aged 12 to 17 years. 178 The adult (mean age = 46 years) trials consisted of one 12-week (Trial 1), 2 replicate 24-week (Trials 2 and 3), and 2 replicate 48-week (Trials 4 and 5) randomized, double-blind, placebo-controlled trials in adults with asthma. All trials included inhaled corticosteroid background therapy (additional asthma treatments were also allowed) and rescue therapy. All trials were funded by the manufacturer.
Trial 1 compared once daily tiotropium 2.5 mcg, tiotropium 5 mcg, and placebo (n=309). 179 After 12 weeks, the mean difference in peak (primary endpoint) and trough FEV1 of 2.5 mcg compared to placebo were 0.16 L (95% CI, 0.09 to 0.23) and 0.11 L (95% CI, 0.04 to 0.18), respectively (p-values not reported). The FEV1 improvement in the 5 mcg group was generally lower than improvement in the 2.5 mcg (peak data reported only as a composite with other trials; trough FEV1 increased by 11% in this trial, but was decreased in subsequent trials).
Trials 2 and 3 compared tiotropium 2.5 mcg once daily, tiotropium 5 mcg once daily, salmeterol 50 mcg twice daily, and placebo (Trial 2, n=524; Trial 3, n=509). 180 Patients included had a FEV1 of 60% to 90% the predicted value. The primary outcomes were peak FEV1 and trough FEV1 A 2008 meta-analysis of 17 randomized, controlled trials of 14,783 patients was conducted to ascertain the cardiovascular risks including cardiovascular death, myocardial infarction (MI), and stroke of inhaled anticholinergics (tiotropium or ipratropium bromide) versus control therapy (inhaled salmeterol, inhaled salmeterol/fluticasone, inhaled albuterol, or placebo). 183 The study selection included trials of at least 30 days duration and reported on cardiovascular events. The primary outcome was a composite of cardiovascular death, MI, or stroke. The secondary outcome was all-cause mortality. The authors state that cardiovascular death is a more frequent cause of death in patients with COPD than respiratory causes. Based on the results, inhaled anticholinergics significantly increased the risk of the composite outcome of cardiovascular death, MI, or stroke (1.8% versus 1.2% for control; p<0.001). Further delineation for individual primary outcomes were also assessed and showed inhaled anticholinergics significantly increased the risk of MI (1.2% versus 0.8%, p=0.03) based on 11 trials involving 10,598 patients. Risk of cardiovascular death was significantly increased by inhaled anticholinergics (0.9% versus 0.5%, p=0.008) in 12 trials of 12,376 patients. On the other hand, inhaled anticholinergics did not significantly increase the risk of stroke (0.5% versus 0.4% for control, p=0.2). Inhaled anticholinergics also did not significantly increase the risk of all-cause mortality (2% versus 1.6%; p=0.06). Important to note in the meta-analysis is that many of the trials included were small and short-term, none of them were specifically designed to monitor risk of cardiovascular events, and some of the reporting of cardiovascular outcomes may have been incomplete. Further prospective studies that are adequately powered are needed to assess the cardiovascular safety of the inhaled anticholinergics. In the meantime, the risks of adverse events (e.g., MI or cardiovascular death) versus benefits of symptomatic improvement (e.g., increase in exercise capacity, reduced COPD exacerbations and hospitalizations, and improved dyspnea) must be weighed when using the inhaled anticholinergics. Unfortunately, alternative therapeutic options are limited for patients with COPD due to their differing adverse effect profiles.
Results from a systematic search including studies from MEDLINE and the Cochrane databases between 1966 and March 2007 on inhaled therapies and disease management were used to determine the effectiveness of management strategies for COPD (including inhaled therapies) in regards to exacerbations, hospitalization, deaths, and adverse effects. 184 Treatment was recommended for patients with stable COPD who have respiratory symptoms and FEV1 < 60%. Treatment should consist of one of the following: long-acting inhaled beta-agonist, long-acting inhaled anticholinergic, or inhaled corticosteroid. There was insufficient documentation to recommend 1 monotherapy over another since they had similar effectiveness although different adverse effects, reductions in deaths, and hospitalizations were observed. Studies of combination therapies do not consistently show benefits of combination therapy over monotherapy.
More questions will be generated as a result of a meta-analysis of 22 randomized, double-blind, placebo or active-controlled trials with 15,276 patients. 185 The meta-analysis evaluated the safety and efficacy of anticholinergics (ipratropium and tiotropium) and beta2 agonists (albuterol, metaproterenol, formoterol, and salmeterol) in COPD. Anticholinergics significantly reduced severe COPD exacerbations compared to placebo, as well as reduced respiratory deaths. On the contrary, beta2 agonists did not affect severe COPD exacerbations and actually increased the rate of respiratory deaths compared with placebo.
A meta-analysis of 28 trials (n=14,909) comparing tiotropium (Spiriva HandiHaler or Spiriva Respimat) to placebo found a lower risk of adverse effects (rate ratio [RR], 0.9; 95% CI, 0.87 to 0.93), serious adverse effects (RR, 0.94; 95% CI, 0.89 to 0.99), and fatal adverse effects (RR, 0.9; 95% CI, 0.79 to 1.01) compared to placebo. 186 Likewise, a meta-analysis of 12 randomized controlled trials evaluating the efficacy of aclidinium in 9,547 patients with COPD also found a benefit with this agent compared to placebo. 187 Aclidinium lowered the SGRQ total score (improved quality of life) by mean difference of -2.34 (95% CI, -3.18 to -1.51; 7 trials, 4,442 participants) when compared to placebo. Aclidinium also significantly improved pre-dose FEV1 compared to placebo (mean difference, 0.09 L; 95% CI, 0.08 to 0.1; 9 trials, 4,963 participants). However, no difference was found in all-cause mortality.
A meta-analysis of 27 randomized controlled trials (≥ 12 weeks duration) assessed the efficacy of longacting anticholinergics (e. 3), respectively. Significant differences were also seen with each agent compared to placebo in SGRQ improvement and rescue medication use; however, no significant differences were found between agents.
A meta-analysis of 27 trials (n=30,361) comparing efficacy of fixed-dose combinations of LABAs and long-acting anticholinergic agents (e.g., aclidinium/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, and umeclidinium/vilanterol) found that all agents have similar efficacy. 190 Notably, the aclidinium combination product is not available in the U.S. A Cochrane review compared the efficacy of the combination of a LABA/ICS and tiotropium to either LABA/ICS or tiotropium alone. 191 Data were limited and the authors could not compare tiotropium plus LABA/ICS to LABA/ICS alone, but they were able to make comparisons for tiotropium plus LABA/ICS to tiotropium alone based on date from 6 trials (n=1,902). They found no differences with the addition of a LABA/ICS to tiotropium in mortality (OR, 1.8; 95% CI, 0.55 to 5.91) but did find a difference in all-cause hospitalizations (OR, 0.61; 95% CI, 0.4 to 0.92) and quality of life as measured by the SGRQ (mean difference, -3.46; 95% CI, -5.05 to -1.87) favoring the combination.
Asthma
Meta-analyses in asthma patients have also demonstrated superiority of tiotropium compared to placebo in adults and adolescents. A meta-analysis of 13 studies in 4,966 COPD patients ≥ 12 years of age found a significant improvement in asthma control with tiotropium (multiple formulations; as addon therapy) compared to placebo (peak expiratory flow, 22 to 24 L/min; FEV1, 140 to 150 mL; NNT for decreased exacerbations, 36). 192 A similar meta-analysis of 3 studies in adolescents (ages) found significant improvements in change in FEV1 peak (mean difference, 120 mL; p<0.001) and trough (mean difference, 100 mL; p<0.001) with tiotropium (Spiriva Respimat) compared to placebo. 193 A significant difference was also seen in the percentage of patients who experienced an ACQ-7 worsening episode (defined as a change of ≥ 0.5) with tiotropium compared with placebo (2.1% versus 4.8%; number needed to treat [NNT]=38). Tiotropium also significantly decreased in the number of patients with at least 1 exacerbation compared with placebo (17.6% versus 23.8%, NNT=16). No significant differences in rescue medication use, withdrawals, withdrawals due to adverse events, and serious adverse effects were identified. A Cochrane review of 3 double-blind, randomized controlled trials comparing the addition of LAMAs (only tiotropium trials were included) to LABA/ICS therapy to LABA/ICS therapy alone in adults with asthma did not find a statistically significant difference in exacerbations (OR, 0.76; 95% CI, 0.57 to 1.02). 194 However, the authors noted that there was a trend toward significance and data were limited to rule out a possible benefit. No clinical difference was seen in quality of life, as measured by the Asthma Quality of Life Questionnaire and defined as a change ≥ 0.5 (mean difference, 0.09; 95% CI, 0.24 to 1.47), or serious adverse effects.
SUMMARY
The combined COPD assessment illustrated in the 2016 updated GOLD guidelines incorporates spirometric abnormality, as well as symptoms, exacerbation/hospitalization history, and comorbidities to help guide intervention, assigning patients to mixed severity-risk stratification groupings. Consequently, more focus can be placed on the goals of treatment, which are to reduce symptoms and risks while minimizing adverse effects. Treatment initiation may begin with the use of as-needed, short-acting bronchodilators followed by routine long-acting bronchodilators, inhaled corticosteroids, phosphodiesterase-4 (PDE4) inhibitors, long-term oxygen therapy, and even surgery. Regular use of long-acting beta2-agonists or short-or long-acting anticholinergics has been shown to improve health status.
Albuterol is available in combination with ipratropium in a CFC-free MDI (Combivent Respimat) and as an inhalation solution for the treatment of COPD. The combination CFC-free MDI may be beneficial in reducing the number of puffs per day required as compared to treatment with the individual components.
Umeclidinium/vilanterol (Anoro Ellipta), formoterol/glycopyrrolate (Bevespi Aerosphere), indacaterol/glycopyrrolate (Utibron Neohaler), and tiotropium/olodaterol (Stiolto Respimat), once-or twice-daily anticholinergic/LABA combinations, offer another option for the long-term maintenance treatment of COPD, for patients inadequately controlled with a single long-acting bronchodilator. For patients with moderate to severe airflow obstruction and chronic symptoms, the guidelines recommend maintenance treatment with an inhaled long-acting bronchodilator, either alone or in combination with other agents depending on disease severity. The single-agent anticholinergic options in this class are aclidinium (Tudorza Pressair), glycopyrrolate (Seebri Neohaler), ipratropium (Atrovent), tiotropium (Spiriva, Spiriva Respimat), and umeclidinium (Incruse Ellipta). The long-acting, tiotropiumand umeclidinium-containing agents are dosed once daily with a duration of action of 24 hours or greater. Aclidinium and glycopyrrolate-containing formulations, also long-acting, are dosed twice daily. Ipratropium requires up to 4 administrations daily. All of these agents have been shown to improve bronchodilation, dyspnea, exacerbation rates, and health-related quality of life. Adverse effects for anticholinergic agents are limited primarily to dry mouth that appears to resolve with continued use. The GOLD guidelines do not recommend 1 anticholinergic agent or combination product over another and therapy should be individualized based on the patient's limitation of airflow, symptoms, exacerbations, and comorbidities.
Roflumilast (Daliresp) is the only selective phosphodiesterase-4 (PDE4) inhibitor approved as a treatment option in COPD management. Unlike the other inhaled treatment options currently available, roflumilast is an oral tablet formulation taken once daily. Roflumilast is not a bronchodilator; it acts on the underlying inflammation and is not indicated for the relief of acute bronchospasm. Roflumilast's modest benefit appears primarily to be demonstrated in patients with chronic bronchitis and frequent exacerbations.
In addition to its COPD indication, tiotropium inhalation spray (Spiriva Respimat) also carries an indication for asthma in patients ≥12 years of age. Efficacy has been demonstrated as add-on therapy to an inhaled corticosteroid (with or without other background therapies) in patients with asthma who are not controlled on their current regimen. Its role in practice guidelines has not been fully elucidated, but it serves as a treatment option in latter stages of step-wise therapy.
